Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LM-350 |
| Trade Name | |
| Synonyms | LM350|LM 350 |
| Drug Descriptions |
LM-350 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH17 linked to the topoisomerase I inhibitor LDX2, which potentially induces cytotoxicity in CDH17-positive tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 2868). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| LM-350 | LM-350 | 0 | 1 |